Introduction {#S1}
============

Dopamine D~4~ receptors are expressed in the prefrontal cortex (PFC), in GABAergic interneurons and in glutamatergic pyramidal neurons, including their striatal projections.^[@R1]--[@R3]^ D~4~ receptors have been implicated in ADHD.^[@R1],[@R4],[@R5]^ In fact, the PFC and associated fronto-striatal circuits are critical for executive function and are involved in ADHD.^[@R5]^ The gene encoding the human D~4~ receptor contains a large number of polymorphisms in its coding sequence.^[@R4]^ The most extensive polymorphism is found in exon 3, a region that codes for the third intracellular loop (3IL) of the receptor. This polymorphism consists of a variable number of tandem repeats (VNTR) in which a 48-bp sequence exists as 2- to 11-fold repeats.^[@R7]^ The three most common variants contain two, four and seven repeats (D~4.2~, D~4.4~ and D~4.7~, respectively). D~4.4~ constitutes the most frequent variant, with a global frequency of 64%, followed by D~4.7~ (21%) and D~4.2~ (8%).^[@R8]^ Importantly, a high prevalence of the D~4.7~ variant has been demonstrated in children diagnosed with ADHD.^[@R5]^ Though stimulation of the D~4,7~ variant has been reported to be less potent at inhibiting cAMP than D~4.2~ or D~4.4~,^[@R9]^ the functional significance of these variants are poorly understood.

Receptor heteromers are becoming the focus of extensive research in the field of G-protein-coupled receptors.^[@R10]^ A receptor heteromer is currently defined as a macromolecular complex composed of at least two (functional) receptor units with biochemical properties that are demonstrably different from those of its individual components.^[@R10]^ In some cases, receptor heteromers provide a framework in which to understand the role of receptors with no clear functional significance, and example being the D~3~ receptor, which forms heteromers with the D~1~ receptor and modifies its function.^[@R11]^ A recent study showed that in mammalian transfected cells the long isoform of the D~2~ receptor (D~2L~) heteromerizes with the three main D~4~ receptor variants, D~4.2~, D~4.4~. and D~4.7~.^[@R12]^ Interestingly, results from the same study suggested that D~4.7~ was less effective in forming heteromers with D~2L~ receptors.^[@R12]^ In view of the reported evidence of predominant co-localization of D~4~ receptors with the short isoform of the D~2~ receptor (D~2S~) in cortico-striatal glutamatergic terminals,^[@R2],[@R3],[@R13]^ we first investigated if any of the three main human variants of the D~4~ receptor could interact both physically and functionally with D~2S~. By using the Bioluminescence Resonance Energy Transfer (BRET) technique, here we show evidence for the formation of heteromers between D~2S~ and D~4.2~ and D~4.4~ variants of the D~4~ receptor. In contrast, the D~4.7~ variant failed to form heteromers with the D~2S~ receptor. In transfected cells we found a biochemical property of the D~2S~-D~4~ receptor heteromer, which consists of the ability of D~2S~ receptor activation to potentiate D~4~ receptor-mediated MAPK signaling. A similar result was observed in striata from wild-type mice, a species that expresses D~4~ receptors with a short 3IL comparable to human D~4.2~. In contrast, potentiation of D~4~ receptor-mediated MAPK signaling was not observed in transfected cells expressing D~4.7~ or in striata taken from *knock-in* mice carrying a humanized 7 repeat intracellular loop identical to that found in human D~4.7~. Finally, analyzing neurotransmitter release in striatal slices and with *in vivo* microdialysis in rats, evidence was obtained for a key role of D~2~-D~4~ receptor interaction in the modulation of striatal glutamatergic neurotransmission.

Materials and methods {#S2}
=====================

Fusion Proteins and Expression Vectors {#S3}
--------------------------------------

The synthetic cDNAs for the human D~4.2~, D~4.4~ and, D~4.7~ receptor gene (kindly provided by T.P. Sakmar, Rockefeller University, USA) were amplified using sense oligonucleotide primer (5´- TCAACGGGACTTTCCAAAATGT-3´) and antisense primer (5´ CTCCGAGATCAACTTCTGCTCGCTTCGGTTACCC-3´) resulting in a cDNA fragment of 200 bp. A second product was generated using the sense oligonucleotide primer (5´- AAGTTGATCTCGGAGGAAGATACAGCAGATGCAG-3´) and antisense primer (5´- GCGAATTCGCAGCAAGCACGTAGAGCCTTACG-3´) resulting in a cDNA fragment of 1500 bp. Equimolar quantities of both fragments were used to produce a third product corresponding to the myc-D~4.2~, myc-D~4.4~ or myc-D~4.7~ tagged gene using the sense primer (5´- GTGCTCGAGCACCATGGGTAACCGAAGCACAG-3´) and antisense primer without its stop codon (5´- GCGAATTCTCAGCAGCAAGCACGTAGAGCCTTACG-3´) harbouring unique XhoI and EcoRI restriction sites, respectively. The fragments were then subcloned in-frame into XhoI/EcoRI sites of the pcDNA3.1 vector (Invitrogen). Next, the human cDNAs for the adenosine A~1~ receptor and dopamine D~4.2~, D~4.4~, D~4.7~ and D~2S~ receptors, cloned in *pcDNA3.1* were amplified without their stop codons using sense and antisense primers harboring unique XhoI and EcoRI sites to clone A~1~, D~4.2~, D~4.4~ and D~4.7~ receptors in the RLuc and the YFP corresponding vectors, and HindIII and BamHI to clone D~2S~ in the RLuc and the YFP corresponding vectors. The mouse cDNAs for the D~4~ and D~2S~ receptors, cloned in pCMV-SPORT6 (ATCC, Manassas, USA) and pReceiver-M16 vectors respectively (GeneCopoeia, Rockville, USA), were amplified without their stop codons using sense and antisense primers harboring unique XhoI and EcoRV sites to clone D~4~ receptor in the RLuc corresponding vector, and XhoI and KpnI to clone D~2S~ receptor in the RLuc and the YFP corresponding vectors. The amplified fragments were subcloned to be in-frame into restriction sites of the multiple cloning sites of EYFP-N3 vector (enhanced yellow variant of YFP; Clontech, Heidelberg, Germany) or the mammalian humanized pRluc-N1 vectors (Perkin-Elmer, Waltham, MA, USA) to give the plasmids that express the receptors fused to either Rluc or YFP on the C-terminal end of the receptor (D~4.2~-RLuc, D~4.4~-RLuc, D~4.7~-Rluc, D~2S~-RLuc and A~1~-RLuc or D~2S~-YFP, D~4.7~-YFP, and D~1~-YFP, respectively). All constructs were verified by nucleotide sequencing and the fusion proteins are functional and expressed at the membrane level (see Results).

Cell Culture and transient transfection {#S4}
---------------------------------------

Human embryonic kidney (HEK)-293T cells were grown in Dulbecco's modified Eagle's medium (DMEM) (Gibco Paisley, Scotland, UK) supplemented with 2 mM L-glutamine, 100 U/ml penicillin/streptomycin, and 5% (v/v) heat inactivated Foetal Bovine Serum (FBS) (all supplements were from Invitrogen, Paisley, Scotland, UK). CHO cell lines were maintained in α-MEM medium without nucleosides, containing 10% fetal calf serum, 50 µg/ml penicillin, 50 µg/ml streptomycin and 2 mM L-glutamine (300 µg/mL). Cells were maintained at 37°C in an atmosphere of 5% CO~2~, and were passaged when they were 80--90% confluent, twice a week. HEK-293T or CHO cells growing in 6-well dishes or in 25 cm^2^ flasks were transiently transfected with the corresponding fusion protein cDNA by the PEI (PolyEthylenImine, Sigma, Steinheim, Germany) method as previously described.^[@R14]^

Immunostaining {#S5}
--------------

For immunocytochemistry, HEK-293T cells were grown on glass coverslips and transiently transfected with 1 µg of cDNA corresponding to human D~4.2~-RLuc, D~4.4~-RLuc or D~4.7~-RLuc and 0.5 µg of cDNA corresponding to human D~2S~-YFP or 0.8 µg of cDNA corresponding to mouse D~4~-RLuc and 0.5 µg of cDNA corresponding to mouse D~2S~-YFP. After 48h of transfection cells were fixed in 4% paraformaldehyde for 15 min and washed with phosphate-buffered saline contraining 20 mM glycine to quench the aldehyde groups. After permeabilization with phosphate-buffered saline containing 0.05% Triton X-100 for 15 min, cells were treated with phosphate-buffered saline containing 1% bovine serum albumin. After 1 h at room temperature, cells were labeled with the primary rabbit monoclonal anti-human D~4~ receptor (1/10.000, Abcam, Cambridge, UK) or with the primary goat polyclonal anti-D~4~ receptor (1/500, Santa Cruz Biotechnology) for 1 h, washed and stained with the secondary antibody Cy3 anti-rabbit (1/200, Jackson ImmunoResearch, Baltimore, PA) or with the secondary antibody Cy3 anti-goat (1/200, Jackson ImmunoResearch, Baltimore, PA). The D~2S~-YFP construct was detected by its fluorescence properties. Samples were rinsed and observed in an Olympus confocal microscope.

BRET assay {#S6}
----------

HEK-293T cells were co-transfected with a constant amount of cDNA encoding for the receptor fused to Rluc and with increasingly amounts of cDNA encoding to the receptor fused to YFP to measure BRET as previously described (23). Both fluorescence and luminescence for each sample were measured before every experiment to confirm similar donor expressions (approximately 100,000 bioluminescence units) while monitoring the increase in acceptor expression (2000 to 20,000 fluorescence units). The relative amounts of BRET acceptor are expressed as the ratio between the net fluorescence of the acceptor and the luciferase activity of the donor being the net fluorescence the fluorescence of the acceptor minus the fluorescence detected in cells only expressing the donor. The BRET ratio is defined as \[(emission at 510--590)/(emission at 440--500)\] - Cf, where Cf corresponds to (emission at 510--590)/(emission at 440--500) for the D~4~-RLuc or D~2S~-Rluc constructs expressed alone in the same experimental conditions. Curves were fitted by using a non-linear regression equation, assuming a single phase with GraphPad Prism software (San Diego, CA, USA).

Generation of knockin mutant mice carrying human expansions in the 3IL of the D~4~ receptor {#S7}
-------------------------------------------------------------------------------------------

A targeting vector was designed such that coding sequences of the 3IL of mouse *Drd4* were replaced by human ortholog sequences corresponding to the most frequent 7-VNTR human variant allele (see [Figure 4](#F4){ref-type="fig"}). The vector included a selectable PGK-*neo* cassette, flanked by two loxP sites, placed just downstream of *Drd4* polyadenylation site and an HSV-thymidine kinase cassette placed at one of the extremes of the targeting vector to select for the absence of random integrations. A long and short arm of *Drd4* homology were inserted flanking the swapped sequence and the selectable marker, respectively. The linearized vector was used to electroporate hybrid 129svev/C57BL/6 ES cells (inGenious Targeting Laboratory Inc., USA) and homologous recombinant clones were selected in the presence of G418 and gancyclovir. Two selected clones carrying the human 7-VNTR were used to microinject C57BL/6J blastocysts and one high percentage chimeric male mouse was used to produce heterozygote *Drd4^+/7repeat.neo^* mice. The neo cassette was excissed from the recombinant allele by crossing mutant mice with transgenic mice expressing Cre recombinase from an EIIa promoter (Jackson Laboratories, USA; Cat. No. 003724). The resulting heterozygote *Drd4^+/7repeat^* (D~4.7~ knockin) mice were successively bred to C57BL/6J mice to obtain a congenic heterozygote strain (n=10) that was used to establish a breeding colony. Homozygous D~4.7~ knockin mice and their wild-type littermates were used for the experiments. Knockin animals were characterized as indicated in [Figure 4](#F4){ref-type="fig"}.

Mouse striatal slices preparation {#S8}
---------------------------------

Mice were housed five per cage in a temperature (21 ± 1°C) and humidity-controlled (55 ± 10%) room with a 12:12 hours light/dark cycle (light between 08:00 and 20:00 hours) with food and water *ad libitum*. All animal procedures were conducted according to standard ethical guidelines (National Institutes of Health Animal care guidelines and European Communities Council Directive 86/609/EEC) and approved by the Local Ethical and Animal Care Committees. Transgenic mice and litter-mattes were decapitated with a guillotine and the brains were rapidly removed and placed in ice-cold oxygenated (O~2~/CO~2~:95%/5%) Krebs-HCO3^−^ buffer (124 mM NaCl, 4 mM KCl, 1.25 mM NaH~2~PO~4~, 1.5 mM MgCl~2~, 1.5 mM CaCl~2~, 10 mM glucose and 26 mM NaHCO~3~, pH 7.4). The brains were sliced at 4°C in a brain matrix (Zivic Instruments, Pittsburgh, PA, USA) into 0.5 mm coronal slices. Slices were kept at 4°C in Krebs-HCO~3~^−^ buffer during the dissection of the striatum. Each slice was transferred into an incubation tube containing 1 ml of ice-cold Krebs-HCO~3~^−^ buffer. The temperature was raised to 23°C and after 30 min, the media was replaced by 2 ml Krebs-HCO~3~^−^ buffer (23°C).

ERK phosphorylation assay {#S9}
-------------------------

Striatal slices from transgenic mice and litter-mattes were incubated under constant oxygenation (O~2~/CO~2~:95%/5%) at 30°C for 4--5 h in an Eppendorf Thermomixer (5 Prime, Inc., Boulder, CO, USA) with Krebs-HCO~3~^−^ buffer. The media was replaced by 200 µl of fresh Krebs-HCO~3~^−^ buffer and incubated for 30 min before the addition of ligands. Transfected CHO cells were cultured in serum-free medium for 16 h before the addition of the indicated concentration of ligands for the indicated time. Both, cells and slices were lysed in ice-cold lysis buffer (50 mM Tris- HCl pH 7.4, 50 mM NaF, 150 mM NaCl, 45 mM β-glycerophosphate, 1% Triton X-100, 20 µM phenylarsine oxide, 0.4 mM NaVO~4~ and protease inhibitor cocktail). Cellular debris was removed by centrifugation at 13,000 g for 5 min at 4°C and protein was quantified by the bicinchoninic acid method using bovine serum albumin dilutions as standard. To determine the level of ERK1/2 phosphorylation, equivalent amounts of protein (10 µg) were separated by electrophoresis on a denaturing 10% SDS-polyacrylamide gel and transferred onto PVDF-FL membranes. Odyssey blocking buffer (LICOR Biosciences, Lincoln, Nebraska, USA) was then added and membranes were blocked for 90 min. Membranes were then probed with a mixture of a mouse anti-phospho-ERK 1/2 antibody (1:2500, Sigma, Steinheim, Germany) and rabbit anti-ERK 1/2 antibody (1:40000, Sigma) for 2--3 h. Bands were visualized by the addition of a mixture of IRDye 800 (anti-mouse) antibody (1:10000, Sigma) and IRDye 680 (anti-rabbit) antibody (1:10000, Sigma) for 1 h and scanned by the Odyssey infrared scanner (LICOR Biosciences, Lincoln, Nebraska, USA). Bands densities were quantified using the scanner software and exported to Excel (Microsoft, Redmond, WA, USA). The level of phosphorylated ERK1/2 isoforms was normalized for differences in loading using the total ERK protein band intensities.

In vivo microdialysis in rat striatum {#S10}
-------------------------------------

Male Sprague-Dawley rats (Charles River Laboratory, Wilmington, MA, USA), weighing 300--350 g were used. Concentric microdialysis probes with 2-mm long dialysis membranes were prepared as described previously.^[@R15]^ Animals were anesthetized with Equithesin (NIDA Pharmacy, Baltimore, MD, USA) and microdialysis probes were implanted in the ventral striatum (core of the nucleus accumbens); coordinates with respect to bregma: A 1.7, L +1.2 and V -7.6 mm. The experiments were performed on freely moving rats 24 h after the probe implantation. A Ringer solution (in mmol/l) of 147 NaCl, 4 KCl, and 2.2 CaCl~2~ was pumped through the dialysis probe at a constant rate of 1 µl/min. After a washout period of 90 min, samples were collected at 20-min intervals and split into two fractions of 10 µL, to separately measure glutamate and dopamine contents. Each animal was used to study the effect of one treatment by local administration (perfusion by reverse dialysis) of the D~4~ receptor agonist RO-10-5824 or the D~4~ receptor antagonist L-745,870. At the end of the experiment, rats were killed with an overdose of Equithesin and methylene blue was perfused through the probe. The brain was removed and placed in a 10% formaldehyde solution, and coronal sections were cut to verify the probe location. Dopamine content was measured by reverse high-performance liquid chromatography (HPLC) coupled to an electrochemical detector, as described in detail previously.^[@R15]^ Glutamate content was measured by HPLC coupled to a flourimetric detector, as described before.^[@R16]^ The limit of detection (which represents three times baseline noise levels) for dopamine and glutamate was 0.5 and 50 nM, respectively. Dopamine and glutamate values were transformed as percentage of the mean of the three values before the stimulation and transformed values were statistically analyzed with one-way repeated measures ANOVA followed by Newman-Keuls tests, to compare glutamate and dopamine values of the samples obtained after drug perfusion with those obtained just before drug perfusion.

Neurotransmitter release in rat striatal slices {#S11}
-----------------------------------------------

Rat brain slices were obtained from male Wistar rats weighing 180--220 g. After rapid sacrifice of the rat, the brain was immersed in oxygenated ice-cold artificial cerebrospinal fluid (ACSF) solution, and coronal brain slices (300 µm thick) were obtained with a vibratome. The striatum (caudate-putamen and nucleus accumbens) was microdissected under a stereoscopic microscope and the slices were incubated for 30 min at 37°C in ACSF (in mM: NaCl 118.25, KCl 1.75, MgSO~4~ 1, KH~2~PO~4~ 1.25, NaHCO~3~ 25, CaCl~2~ 2, and D-glucose 10.), gassed continuously with O~2~/CO~2~ (95:5, v/v). For GABA release, the slices were then incubated for 30 min with 8 nM \[^3^H\]GABA in 2 ml solution containing 10 µM aminooxyacetic acid (to inhibit GABA transaminase, thus preventing degradation of the labeled GABA). At the end of this period, excess radiolabeled compound was removed by washing twice with ACSF containing, in addition to aminooxyacetic acid and 10 µM nipecotic acid (to prevent the reuptake of the released \[^3^H\]GABA). Both compounds were present in the perfusion solution for the rest of the experiment. For dopamine release, the slices were labeled with 77 nM \[^3^H\]dopamine in Krebs--Henseleit solution containing 10 µM pargyline, 0.57 mM ascorbic acid and 0.03 mM EDTA, which were present in the solutions for the rest of the experiment. For glutamate release, the tissues were incubated for 30 min with 100 nM \[^3^H\]glutamate in 2 ml of artificial CSF containing 200 µM aminooxyacetic acid (to inhibit glutamate decarboxylase and prevent the conversion of glutamate to GABA) and 200 µM dihydrokainic acid (to prevent the uptake of \[^3^H\]glutamate by astrocytes). Dihydrokainic acid was present in the medium only during the incubation period. At the end of this period, the excess radiolabeled compound was removed by washing twice with artificial CSF. Methods for measuring \[^3^H\]neurotransmitter release and data analysis used in the present work were the same as those described previously.^[@R17],[@R18]^ The slices were apportioned randomly between the chambers (usually three slices per chamber) of a superfusion system (volume of each chamber 80 µl; 20 chambers in parallel) and perfused with the artificial CSF at a flow rate of 0.5 ml/min for 1 h. Basal release of \[^3^H\]neurotransmitter was measured by collecting 4 fractions of the superfusate (total volume 2 ml) before depolarizing the slices with a solution in which the \[K^+^\] was raised to 25 mM. The composition of the high K^+^ solution was (in mM): NaCl 101.25, KCl 23.75, MgSO~4~ 1, KH~2~PO~4~ 1.25, NaHCO~3~ 25, CaCl~2~ 2 and D-glucose 10. Six more fractions were collected in the high K^+^ medium. All drugs were added to the medium at fraction 2, before changing the superfusion to the high K^+^ medium, to explore effects on basal release. To determine the total amount of tritium remaining in the tissue, the slices were collected, treated with 1 ml of 1 M HCl and allowed to stand for 1 h before adding the scintillator. The \[^3^H\]neurotransmitter release was expressed initially as a fraction of the total amount of tritium remaining in the tissue. The effect of drugs on the basal release of \[^3^H\]neurotransmitter was assessed by comparing the fractional release in fraction 2 (immediately before exposure of the tissue to the drug) and fraction four (immediately prior to exposure to 25 mM of K^+^), using Student's paired *t* test. Changes in depolarization-induced \[^3^H\]GABA release by drugs and treatments, were assessed by comparing the area under the appropriate release curves between the first and last fractions collected after the change to high K^+^. The significance of drug effects was assessed by one-way ANOVA and Tukey-Kramer test, using Prism Graph Pad Software 4.0, (Graph Pad Software, San Diego CA, USA). To obtain an unbiased estimate of IC~50~ values, concentration-response data were fitted by non-linear regression using the same software.

Statistical Analysis {#S12}
--------------------

Statistical analyses were performed with Prism Graph Pad Software 4.0, (Graph Pad Software, San Diego CA, USA). See above and figure legends for details.

Results {#S13}
=======

D~2S~ and D~4~ receptors form heteromers in transfected cells {#S14}
-------------------------------------------------------------

BRET experiments were performed where one of the receptor is fused to the bioluminescent protein *Renilla Luciferase* (RLuc) and the other receptor is fused to a yellow fluorescent protein (YFP). The fusion proteins were functional ([Supplementary Figure 1](#SD1){ref-type="supplementary-material"}) and expressed at the membrane level ([Figure 1c](#F1){ref-type="fig"}). Clear BRET saturation curves were obtained in cells expressing D~4.2~-RLuc or D~4.4~-RLuc receptors and increasing amounts of D~2S~-YFP ([Figure 1a](#F1){ref-type="fig"}), but not in cells expressing D~4.2~-RLuc or D~4.4~-RLuc receptors and increasing amounts of D~1~-YFP ([Figure 1a](#F1){ref-type="fig"}), indicating that the D~4.2~ and the D~4.4~ form heteromers with D~2S~ but not with D~1~ receptors. Interestingly, in cells expressing the D~4.7~-Rluc variant and D~1~-YFP or D~2S~-YFP ([Figure 1a](#F1){ref-type="fig"}) low linear BRET was detected, which was qualitatively similar to the results obtained with the negative control, with adenosine A~1~-RLuc and D~2S~-YFP receptors ([Figure 1a](#F1){ref-type="fig"}). This result was not due to the particular BRET donor and acceptor chosen, as low and linear BRET were obtained when we swapped the fused proteins, i.e., in cells co-expressing D~2S~-Rluc and D~4.7~-YFP ([Figure 1a](#F1){ref-type="fig"}). These results strongly suggest that the human D~4.7~ polymorphic variant does not form heteromers with the human D~2S~ receptor or if heteromers are formed, the fusion proteins are not properly oriented or are not within proximity to allow energy transfer (less than 10 nm). One way to test if the receptors are indeed forming heteromers in such a way that impedes energy transfer is to titrate one receptor in the presence of the heteromer and look for changes in the BRET signal. In BRET displacement experiments, D~4.2~, but not D~4.7~ receptors were able to compete with D~4.4~-Rluc and alter heteromer formation with D~2S~-YFP ([Figure 1b](#F1){ref-type="fig"}), meaning that D~4.2~ and D~4.4~, but not D~4.7~ receptors use the same molecular determinants to establish intermolecular interactions with D~2S~ receptor and strongly suggesting that D~4.7~ receptors are unable to form heteromers with D~2S~.

D~2S~-D~4~ receptor heteromer signals through MAPK {#S15}
--------------------------------------------------

To investigate the function of the D~2S~-D~4~ receptor heteromer, MAPK signaling (ERK1/2 phosphorylation) was determined. RO-10-5824 and quinelorane, selective D~4~ and D~2/3~ receptor agonists respectively,^[@R19],[@R20]^ selectively stimulated MAPK in cells transfected with D~4~ or D~2S~ receptors, respectively ([Supplementary Figure 2](#SD1){ref-type="supplementary-material"}). Dose-response experiments with RO-10-5824 showed no significant differences between cells transfected with D~4.2~, D~4.4~ or D~4.7~ receptors ([Supplementary Figure 2](#SD1){ref-type="supplementary-material"}). However, in co-transfected cells, stimulation of D~2S~ receptors potentiated D~4~ receptor-mediated MAPK activation, but not the other way around. Importantly, this functional interaction only occurred in cells transfected with D~~2S~~ and D~4.2~ or D~4.4~, but not in cells expressing D~4.7~ receptors ([Figure 2](#F2){ref-type="fig"}). Since disruption of D~2S~-D~4~ receptor heteromers (by substituting D~4.2~ or D~4.4~ with the D~4.7~ variant) is associated with the loss of the D~2S~-D~4~ receptor interaction at the MAPK level, this interaction constitutes a specific biochemical property of the D~2S~-D~4~ receptor heteromer and can be used as a biochemical fingerprint to detect the heteromer in native tissues.^[@R10]^

D~2S~-D~4~ receptor heteromers in the mouse brain {#S16}
-------------------------------------------------

D~4~ receptors are preferentially expressed in limbic areas and the PFC, where they can be found in interneurons and also projecting neurons.^[@R1]^ In cortico-striatal neurons D~4~ receptors have also been localized at their nerve terminals,^[@R2],[@R3]^ where they can co-localize with D~2S~ receptors.^[@R13]^ We therefore investigated the existence of D~2S~-D~4~ receptor heteromers in the striatum. Biophysical techniques cannot be easily applied in native tissues, but indirect methods can be used, such as the identification of a biochemical property of the heteromer (biochemical fingerprint).^[@R10]^ In this case, the biochemical fingerprint would be the potentiation by D~2S~ receptor activation of D~4~ receptor-mediated MAPK activation, which should not occur with the human D~4.7~ variant. Prior to these experiments with mouse brain, we demonstrated by BRET saturation experiments in transfected cells that the mouse D~2S~ receptor forms heteromers with the mouse D~4~ receptor (which has an amino acid sequence in the 3IL similar to that from the human D~4.2~). Mouse fusion proteins were expressed in the plasma membrane of transfected cells ([Figure 3a](#F3){ref-type="fig"}) and shown to be functional ([Supplementary Figure 3](#SD1){ref-type="supplementary-material"}). Like the human receptors, mouse D~2S~ receptors were found to form heteromers with mouse D~4~ receptors and also with human D~4.4~ receptors, but not with human D~4.7~ receptors ([Figure 3b](#F3){ref-type="fig"}). Furthermore, it was also shown that, in co-transfected cells, stimulation of the mouse D~2S~ receptor potentiates the effect of the mouse D~4~, but not the human D~4.7~, on MAPK signaling ([Figures 3c,d](#F3){ref-type="fig"}). This result was not reciprocal ([Supplementary Figure 4](#SD1){ref-type="supplementary-material"}) and mirrors the results obtained with human D~4~ and D~2S~ receptors ([Figure 2](#F2){ref-type="fig"}). We next analyzed the effects of D~2~ and D~4~ receptor agonists on MAPK signaling on striatal slices taken from knock-in mice carrying the 7 repeats of the human D~4.7~ in replacement of the mouse region and from wild-type littermates ([Figure 4](#F4){ref-type="fig"}). Neither quinelorane nor RO-10-5824 induced a significant ERK1/2 phosphorylation in striatal slices of wild-type mice when administered alone, but co-administration of both agonists produced a significant dose-dependent effect with an increase of up to four fold ([Figure 3e](#F3){ref-type="fig"}). This synergistic interaction between D~2~ and D~4~ receptors, which constitutes the biochemical fingerprint of the D~2S~-D~4~ receptor heteromer, was completely absent in the D~4.7~ mutant mouse ([Figure 3e](#F3){ref-type="fig"}), confirming both the existence of D~2S~-D~4~ receptor heteromers and the absence of functional interactions between D~2~ and D~4.7~ receptors in the brain.

D~2~-D~4~ receptor interactions modulate striatal glutamate release {#S17}
-------------------------------------------------------------------

To investigate the functional significance of D~4~ receptor activation we determined D~4~ receptor-mediated modulation of striatal glutamate release by *in vivo* microdialysis in freely moving rats. The local perfusion of the D~4~ receptor agonist RO-10-5824 in the ventral striatum (in the nucleus accumbens) produced a dose-dependent decrease in the striatal extracellular concentration of glutamate and a concomitant increase in the extracellular concentration of dopamine ([Figure 5a and 5b](#F5){ref-type="fig"}), which were counteracted by co-perfusion with the selective D~4~ receptor antagonist L-745,870 (which was inactive when perfused alone) ([Figure 5a, 5b and 5c](#F5){ref-type="fig"}). These results suggest that inhibitory D~4~ receptors are located in glutamatergic terminals, whose activation decreases basal striatal glutamate release. The increase in dopamine concentration can best be explained by a decreased activation of striatal GABAergic efferent neurons that tonically inhibit dopaminergic mesencephalic neurons. This interpretation could be confirmed in experiments with striatal slices, where dopamine should not be modified due to the interruption of the striatal-mesencephalic loop. In fact, in slices of dorsal or ventral rat striatum, the D~4~ receptor agonist RO-10-5824 decreased K^+^-induced glutamate release, an effect that was counteracted by the selective D~4~ receptor antagonist L-745,870, but did not change dopamine or GABA release ([Figure 6](#F6){ref-type="fig"}), indicating that striatal D~4~ receptors selectively and locally modulate glutamate release. This role of D~4~ receptors in the striatum can also explain previous results obtained with D~4~ receptor KO mice, which show an increase and decrease in the striatal extracellular concentration of glutamate and dopamine, respectively.^[@R21],[@R22]^

As mentioned before, there is evidence for co-localization of both D~2~ and D~4~ receptors in cortico-striatal glutamatergic terminals^[@R2],[@R3],[@R13]^ and previous studies have demonstrated that presynaptic D~2~-like receptors play an inhibitory role in the modulation of striatal glutamate release.^[@R13],[@R23]^ However, since those studies did not use selective compounds, they could not distinguish between effects due to D~2~ or D~4~ receptor stimulation. Therefore, in this study we tested the effect of quinelorane alone and in combination with RO-10-5824 on glutamate release in rat striatal slices. To eliminate endogenous dopamine, rats were treated with reserpine, and the experiments performed in the presence of the D~1~-like receptor antagonist SCH-23390. Quinelorane significantly decreased K^+^-induced glutamate release whereas the co-application of quinelorane with RO-10-5824 showed a more significant effect ([Figure 7a](#F7){ref-type="fig"}). Dopamine strongly decreased K^+^-induced glutamate release, an effect partially counteracted by the D~2~ receptor antagonist L-741,626 or by the D~4~ receptor antagonist L-745,870, but completely counteracted by the simultaneous application of both antagonists ([Figure 7b](#F7){ref-type="fig"}). In agreement with the reported higher *in vitro* affinity of D~4~ versus D~2~ receptor for dopamine,^[@R24]^ the IC~50~ of dopamine-mediated inhibition of K^+^-induced glutamate release was significantly higher in the presence of the D~4~ receptor antagonist (D~2~-mediated effect) than in the presence of the D~2~ receptor antagonist (D~4~-mediated effect) ([Figure 7b](#F7){ref-type="fig"}). Finally, and more importantly, the D~2~ receptor agonist quinelorane synergistically potentiated the inhibitory effect of the D~4~ receptor agonist RO-10-5824 on K^+^-induced glutamate release (significant decrease in IC~50~ value) ([Figure 7c](#F7){ref-type="fig"}), but not the other way around ([Figure 7d](#F7){ref-type="fig"}). These results therefore show the same kind of D~2~-D~4~ receptor interaction demonstrated by D~2S~-D~4~ receptor heteromers in transfected cells with MAPK signaling. Our combined *in vitro* and *in vivo* data strongly suggest that D~2S~-D~4~ receptor heteromers are likely to play a key role in dopamine-mediated modulation of striatal glutamate release

Discussion {#S18}
==========

The present study shows that dopamine D~2S~ and D~4.2~ or D~4.4~ receptors, but not the ADHD-associated human D~4.7~ variant, form functional heteromers in transfected cells and in the rodent brain. Co-stimulation of D~2S~ and D~4~ receptors in the D~2S~-D~4~ receptor heteromer has a synergistic effect on MAPK signaling, which could be demonstrated in transfected cells and in the mouse striatum, but not in cells expressing D~4.7~ or in the striatum of a mutant mouse carrying the 7 repeats of the human D~4.7~ in the 3IL of the D~4~ receptor. These results provide a significant functional difference of one of the human receptor variants, D~4.7~, compared to the D~4.2~ and D~4.4~ variants, which can have important implications for the understanding of the pathogenesis of ADHD. Importantly, we also demonstrated, for the first time, that D~2S~-D~4~ receptor interactions modulate striatal glutamate release suggesting that the D~2S~-D~4~ receptor heteromer allows dopamine to fine-tune glutamate neurotransmission.

The molecular mechanism involved in preventing heteromer formation between D~2S~ and D~4.7~ receptors is not yet known. Indeed, the control of heteromer formation between GPCRs is still a large question in the field. Since the D~4.7~ receptor variant has the longest 3IL and is the only polymorphic form not forming heteromers with the D~2S~ receptor, steric hindrance of the 3IL of D~4.7~ receptor is a probable mechanism responsible for this lack of heteromerization, but other mechanisms cannot be ruled out. Using two-hybrid methodologies as well as proteomic studies, interactions between dopamine receptors and a cohort of dopamine receptor interacting proteins (DRIPs) have been demonstrated, forming signaling complexes or signalplexes.^[@R25],[@R26]^ Some of these DRIPs show selectivity for some dopamine receptor subtypes. For example, filamin or protein 4.1N interact with D~2~ and D~3~ receptors but not with D~1~, D~5~ or D~4~ receptors,^[@R27],[@R28]^ the PDZ domain-containing protein, GIPC (GAIP interacting protein, C terminus) interacts with D~2~ and D~3~ receptor but not with the D~4~ receptor subtype^[@R29]^ and paralemmin interacts exclusively with D~3~, but not with D~2~ or D~4~ receptors.^[@R30]^ All of these interactions modulate receptor targeting, trafficking and signaling. Proline-rich sequences of the D~4~ receptor, mainly located in the polymorphic region of the 3IL, constitute putative SH3 binding domains which can potentially interact with adapter proteins like Grb2 and Nck, which do not have any known catalytic activity but are capable of recruiting multiprotein complexes to the receptor.^[@R24]^ It can be hypothetized that differences in DRIPs recruitment by D~4.7~ and the other D~4~ polymorphic forms can influence the D~4.7~ ability to form heteromers, but future studies will be required.

Previous experiments indicated that locally in the striatum dopamine inhibits glutamate release by activating D~2~ receptors (predominantly D~2S~) localized in glutamatergic terminals.^[@R13],[@R23]^ Other studies also indicate that striatal postsynaptic D~2~ receptors (predominantly D~2L~) indirectly modulate glutamate release by retrograde endocannabinoids signaling.^[@R31]^ The present results indicate that D~4~ receptors also play a key role in the modulation of striatal glutamate release, likely through its ability to form heteromers with presynaptic D~2S~ receptors. In the striatal D~2S~-D~4~ receptor heteromer, low concentrations of dopamine should bind to the D~4~ receptor, which has more affinity for dopamine than the D~2S~ receptor,^[@R24]^ causing a certain degree of inhibition of glutamate release. However, at higher concentrations, dopamine should also bind to the D~2S~ receptor and under these conditions the synergistic interaction in the D~2S~-D~4~ receptor heteromer will produce an even stronger inhibition of glutamate release. Therefore, the D~2S~-D~4~ receptor heteromer seems to act as a concentration-dependent device that establishes two different degrees of presynaptic dopaminergic control over striatal glutamatergic neurotransmission. Since the strong modulation observed with higher concentrations of dopamine depends on D~2S~-D~4~ receptor heteromerization, the existence of a D~4.7~ variant implies a weaker control of glutamatergic neurotransmission, which could be a main mechanism involved in the pathogenesis of ADHD. This could also explain at least part of the so far not understood successful effect of psychostimulants in ADHD, which amplify dopaminergic signaling and these medications appear to be more effective in ADHD patients with the D~4.4~ than with the D~4.7~ variants.^[@R32],[@R33]^ We have to take into account that the existence of a D~4.7~ variant does not imply ADHD is the result of this variant, but rather that it is one factor that contributes to its development. In fact, the D~4.7~ variant might constitute a successful evolutionary trait under the appropriate environmental exposure.^[@R7],[@R34]^ The present study provides a new element of interest in the field of receptor heteromes, which now become new targets to be studied when dealing with functional differences associated with polymorphisms of G-protein-coupled receptor genes.
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![Human D~2S~ and D~4~ receptors form heteromers in transfected cells\
**a)** BRET saturation curves were obtained from experiments with cells co-expressing, top to bottom, D~2S~-YFP and D~4.2~-RLuc (red), D~4.4~-RLuc (green) or D~4.7~-Rluc (blue), D~2S~-RLuc and D~4.7~-YFP (purple), A~1~-RLuc and D~2S~-YFP (black) or D~4.4~-RLuc and D~1~-YFP (gray). Co-transfections were performed with a constant amount of cDNA corresponding to the receptor-RLuc construct (2 µg of cDNA for D~4~-RLuc or 1 µg of cDNA for A~1~-RLuc) and increasing amounts of cDNA corresponding to the receptor-YFP construct (0.2--6 µg of cDNA for D~2S~-YFP or 1--4 µg of cDNA for D~1~-YFP). Both fluorescence and luminescence of each sample were measured prior to every experiment to confirm equal expression of Rluc (about 100,000 luminescence units) while monitoring the increase of YFP expression (2000 to 20,000 fluorescence units). BRET data are expressed as means ± S.D. of four to nine different experiments grouped as a function of the amount of BRET acceptor. (**b**) BRET displacement experiments were performed in cells expressing constant amounts of D~4.4~-RLuc (2 µg cDNA transfected) and D~2S~-YFP (2µg cDNA tranfected) and increasing amounts (1--5 µg of cDNA transfected) of D~4.7~ (blue) or D~4.2~ (green). Both fluorescence and luminescence of each sample were measured prior to every experiment to confirm no changes in the expression of D~4.4~-RLuc and D~2S~-YFP. BRET data are expressed as means ± S.D. of five different experiments grouped as a function of the amount of BRET acceptor. Significant differences with respect to the samples without D~4.2~ or D~4.7~ were calculated by one-way ANOVA and Bonferroni's test. (\*\**P* \< 0.01 and \*\*\*P \< 0.001). In **(a)** and **(b)** the relative amounts of BRET acceptor are expressed as the ratio between the fluorescence of the acceptor minus the fluorescence detected in cells only expressing the donor, and the luciferase activity of the donor. In the top, schematic representations of BRET **(a)** or BRET displacement **(b)** are shown. **(c)** Confocal microscopy images of cells transfected with 1 µg of cDNA corresponding to, left to right, D~4.2~-RLuc, D~4.4~-RLuc or D~4.7~-RLuc and 0.5 µg cDNA corresponding to D~2S~-YFP. Proteins were identified by fluorescence or by immunocytochemistry. D~4~-RLuc receptors are shown in red, D~2S~-YFP is shown in green and co-localization is shown in yellow. Scale bar: 5 µm.](nihms310405f1){#F1}

![Crosstalk between human D~4~ and D~2S~ receptors in ERK 1/2 phosphorylation\
Cells were transiently co-transfected with 2.5 µg of cDNA corresponding to D~2S~ and 2.5 µg of cDNA corresponding to D~4.2~ (**a** and **d**), D~4.4~ (**b** and **e**) or D~4.7~ (**c** and **f**). In **a**, **b** and **c**, cells were treated for 10 min with increasing concentrations of RO 10-5824 in the presence (○) or in the absence (●) of quinelorane (50 nM). In **d, e** and **f,** cells were treated for 10 min with increasing concentrations of quinelorane in the presence (○) or in the absence (●) of RO 10-5824 (50 nM). The immunoreactive bands, corresponding to ERK 1/2 phosphorylation, of three to six experiments were quantified and expressed as arbitrary units. For each curve EC~50~ values were calculated as mean ± S.E.M. and statistical differences between curves obtained in the presence or in the absence of quinelorane (**a, b** and **c**) or RO 10-5824 (**d, e** and **f**) were determined by Student's *t* test. EC~50~ with and without quinelorane: **(a)** 9 ± 1 and 26 ± 1nM (p\<0.01), **(b)** 7 ± 1 and 23 ± 1nM (p\<0.01), **(c)** 18 ± 1 and 22 ± 1 nM (N.S.). EC~50~ with and without RO 10-5824: **(d)** 22 ± 1 and 20 ± 1 nM (N.S.), **(e)** 20 ± 1 and 17 ± 1 nM (N.S.), **(f)** 18 ± 1 and 13 ± 1nM (N.S.). N.S.: non-statistical differences](nihms310405f2){#F2}

![D~2s~-D~4~ receptor heteromers in the mouse brain\
**(a)** Confocal microscopy images of cells transfected with 1 µg of cDNA corresponding to, left to right, mouse D~4~-RLuc, human D~4.4~-RLuc and human D~4.7~-RLuc and 0.5 µg of cDNA corresponding to D~2S~-YFP. Proteins were identified by fluorescence or by immunocytochemistry. D~4~-RLuc receptors are shown in red, D~2S~-YFP is shown in green and co-localization is shown in yellow. Scale bar: 5 µm. **(b)** Mouse D~2S~ receptor heteromerization with mouse and human D~4~ receptors. BRET saturation curves were obtained from cells co-expressing mouse D~4~-Rluc (green), human D~4.4~-RLuc (red), human D~4.7~-RLuc (blue) or human A~1~-RLuc (gray) and mouse D~2S~-YFP receptors. Co-transfections were performed with a constant amount of cDNA corresponding to the receptor-RLuc construct (2 µg of cDNA for mouse D~4~-RLuc, 2.5 µg of cDNA for human D~4~-RLuc or 1 µg of cDNA for A~1~-RLuc) and increasing amounts of cDNA corresponding to the receptor-YFP construct (0.2--6 µg cDNA). Both fluorescence and luminescence of each sample were measured prior to every experiment to confirm equal expression of Rluc (about 100,000 luminescence units) while monitoring the increase of YFP expression (2000 to 20,000 fluorescence units). The relative amounts of BRET acceptor are expressed as the ratio between the fluorescence of the acceptor minus the fluorescence detected in cells only expressing the donor, and the luciferase activity of the donor. BRET data are expressed as means ± S.D. of three to six different experiments grouped as a function of the amount of BRET acceptor. **(c)** and **(d)** Crosstalk between mouse D~2S~ receptors and mouse or human D~4~ receptors in ERK 1/2 phosphorylation. Cells transiently co-expressing mouse D~2S~ receptors and mouse D~4~ receptors (**c**) or human D~4.7~ receptors (**d**) were treated for 10 minutes with increasing RO 10-5824 concentrations in the presence (○) or in the absence (●) of quinelorane (50 nM) prior to the ERK 1/2 phosphorylation determination. The immunoreactive bands of three experiments (mean ± SEM; *n* = 3) were quantified and expressed as arbitrary units. EC~50~ values with or without quinelorane were: (c) 7 ± 0.1 and 15 ± 0.1 nM (Student's *t* test: p\<0.01) or **(d)** 18 ± 0.1 and 15 ± 0.1 nM (Student's *t* test: NS). **(e)** Striatal slices from wild-type (WT) or D~4.7~ mutant mice were treated for 10 min with the indicated concentrations of RO 10-5824 (orange) or quinelorane (green) or with RO 10-5824 plus quinelorane (blue) and ERK 1/2 phosphorylation was determined. For each treatment, the immunoreactive bands from 4 to 6 slices from a total 10 WT and 10 D~4.7~ mutant animals were quantified and values represent the mean ± S.E.M. of the percentage of phosphorylation relative to basal levels found in untreated slices (100 %). No significant differences were obtained between the basal levels of the WT and the D~4.7~ mutant mice. Significant treatment and genotype effects were shown by a bifactorial ANOVA followed by post-hoc Bonferroni's tests (\*\* and \*\*\*: p\<0.01 and p\<0.001, respectively, as compared to the lowest concentration of RO 10-5824)](nihms310405f3){#F3}

![Targeted insertion of human VNTRs carrying 7 repeats into the mouse *Drd4* exon 3 by homologous recombination in ES cells\
**(a)** Structure of the *Drd4 locus*, targeting vector and targeted allele. **(b)** Southern blot analysis detected double homologous recombination events at the 5\' and 3\' ends using external probes after digestion with BamHI or EcoRI. **(c)** The presence of inserted human VNTR was verified by PCR using mouse primers flanking the expansion.](nihms310405f4){#F4}

![*In vivo* D~4~ receptor-mediated modulation of basal extracellular levels of glutamate in the rat ventral striatum\
Effects of the local perfusion with the D~4~ receptor agonist RO 10-5824 and the D~4~ receptor antagonist L-745,870 on the basal extracellular concentrations of glutamate (GLU) and dopamine (DA) in the ventral striatum (core of the nucleus accumbens). Horizontal bars show the periods of drug perfusion (concentrations are indicated in M). Data represent means ± S.E.M. of the percentage of the mean of the three basal values before the first drug perfusion (n = 6--8/group): \* and \*\*: p\<0.05 and 0.01, respectively, compared to the values previous in time "0" (repeated measures ANOVA followed by Newman-Keuls tests).](nihms310405f5){#F5}

![D~4~ receptor-mediated modulation of \[^3^H\]glutamate, but not \[^3^H\]dopamine or \[^3^H\]GABA release from slices of dorsal and ventral striatum\
Slices from the dorsal striatum (caudate-putamen; **a, c** and **e)** or the ventral striatum (nucleus accumbens; **b, d** and **f**) of reserpine-treated rats were treated with the D~4~ receptor agonist RO 10-5824 (100 nM) or with the D~4~ receptor antagonist L745,870 (10 nM) alone or in combination and the time course of K^+^ stimulated \[^3^H\]glutamate (**a** and **b**), \[^3^H\]dopamine (**c** and **d**) or \[^3^H\]GABA (**e** and **f**) release was determined. The RO 10-5824-induced effect (open circles) was prevented by the antagonist L 745,870 (dark squares) which itself had no effect (open squares). Values are mean ± S.E.M. of samples from 3 different animals performed in 4 replicates. Drug effect was assessed by comparing the relative area under the curve for each condition. \*\*: p\<0.01 with respect to the control (ANOVA followed by Tukey-Kramer multiple comparison post hoc test).](nihms310405f6){#F6}

![D~2~ and D~4~ receptor interactions in the modulation of striatal \[^3^H\]glutamate release\
Striatal slices (dorsal striatum) from reserpine-treated rats were incubated with SCH 23390 (100 nM) to block D~1~ receptor activation. In (**a**), slices were treated for 32 min (fraction 2 to fraction 10) with medium (control), with the D~4~ receptor agonist RO 10-5824 (100 nM), with the D~2/3~ receptor agonist quinelorane (100 nM) or with both and K^+^ stimulated \[^3^H\]glutamate release was determined. Values are mean ± S.E.M. of samples from 3 different animals performed in 4 replicates. Drug effects were assessed by comparing the relative area under the curve for each condition. \*\*p\<0.01 and \*\*\*p\<0.001 with respect to the control and ^\#\#^ p\<0.01 with respect to slices treated with RO 10-5824 or quinelorane alone (ANOVA followed by Tukey-Kramer multiple comparison post hoc test). In (**b**), slices were treated for 32 min with increasing dopamine concentrations in absence (dark circles) or in the presence of the D~4~ receptor antagonist L-45,870 (10 nM, dark squares), the D~2~ receptor antagonist L 741,626 (10 nM, open circles) or both (open squares) and K^+^ stimulated \[^3^H\]glutamate release was determined. Values are mean ± S.E.M. of samples from 3 different animals performed in 4 replicates. Drug effects were assessed by comparing the relative area under the curve for each condition. The IC~50~ values were: 25.25 nM (C.I.: 9.63--66.20 nM) for dopamine alone, 5.75 nM (2.12--15 nM) for dopamine in the presence of L-741,626 and 357.27 nM (C.I.: 73.40--1739 nM) for dopamine in the presence of L 745,870. In **(c)** slices were treated for 32 min with increasing concentrations of RO 10-5824 in the absence (black circles) or in the presence (open circles) of quinelorane (10 nM) and K^+^ stimulated \[^3^H\]glutamate release was determined. In **(d)** slices were treated for 32 min with increasing concentrations of quinelorane in the absence (black circles) or in the presence (open circles) of RO 10-5824 (10 nM) and K^+^ stimulated \[^3^H\]glutamate release was determined. In **(c)** and **(d)**, values are mean ± S.E.M. of samples from 3 different animals performed in 4 replicates. The IC~50~ values were: (**c**) 15 nM (35.15-6.55 nM) for RO 10-5824 alone and 0.05 nM (1.21-0.02 nM) for RO 10-5824 in the presence of quinelorane (Student's *t* test: p\<0.01) and (**d**) 2.55 nM (7.31-0.89 nM) for quinelorane alone and 1.48 nM (4.5-0.45 nM) for quinelorane in the presence of RO 10-5824 (Student's *t* test; NS).](nihms310405f7){#F7}
